A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression

European Urology

Volumn 66, Issue 3, 2014, Pages 406-413

  Wong, Lih Ming ^a   Alibhai, Shabbir M H ^b   Trottier, Greg ^a   Timilshina, Narhari ^b   Van Der Kwast, Theodorus ^b   Zlotta, Alexandre ^a   Lawrentschuk, Nathan ^a   Kulkarni, Girish ^a   Hamilton, Robert ^a   Ferrara, Sarah ^a   Margel, David ^a   Trachtenberg, John ^a   Jewett, Michael A ^a   Toi, Ants ^b   Evans, Andrew ^b   Fleshner, Neil E ^a   Finelli, Antonio ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Active surveillance; Biopsy; Pathology; Progression; Prostate cancer; Reclassification

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; BLOOD; CANCER GRADING; DISEASE COURSE; DISEASE FREE SURVIVAL; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; WATCHFUL WAITING;

AGE FACTORS; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; WATCHFUL WAITING;

EID: 84905906807     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.04.038     Document Type: Article

References (29)

1. M.A. Dall'Era, P.C. Albertsen, and C. Bangma et al. Active surveillance for prostate cancer: a systematic review of the literature Eur Urol 62 2012 976 983
2. M.R. Cooperberg, P.R. Carroll, and L. Klotz Active surveillance for prostate cancer: progress and promise J Clin Oncol 29 2011 3669 3676
3. J. Tosoian, B.J. Trock, and P. Landis et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185 2190
4. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
5. R.K. Nam, R. Saskin, and Y. Lee et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy J Urol 183 2010 963 969
6. S. Loeb, S. vanden Heuvel, X. Zhu, C. Bangma, F. Schroder, and M. Roobol Infectious complications and hospital admissions after prostate biopsy in a European randomized trial Eur Urol 61 2012 1110 1114
7. W.E. Barzell, M.R. Melamed, P. Cathcart, C.M. Moore, H.U. Ahmed, and M. Emberton Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer J Urol 188 2012 762 768
8. R.J. Babaian, A. Toi, and K. Kamoi et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy J Urol 163 2000 152 157
9. N. Lawrentschuk, M.A. Haider, and N. Daljeet et al. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging BJU Int 105 2010 1231 1236
10. N. Fleshner, M. Lucia, and B. Egerdie et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Lancet Oncol 379 2012 1103 1111
11. National Institutes of Health. Role of active surveillance in the management of men with localized prostate cancer. Draft statement. Paper presented at: National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men with Localized Prostate Cancer; December 5-7, 2011; Bethesda, MD, USA.
12. A.J. Vickers, C. Till, C.M. Tangen, H. Lilja, and I.M. Thompson An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 103 2011 462 469
13. A.E. Ross, S. Loeb, and P. Landis et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810 2816
14. D. Margel, S.A. Yap, and N. Lawrentschuk et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study J Urol 187 2012 1247 1252
15. M. Al-Otaibi, P. Ross, and N. Fahmy et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance Cancer 113 2008 286 292
16. K.S. Tseng, P. Landis, J.I. Epstein, B.J. Trock, and H.B. Carter Risk stratification of men choosing surveillance for low risk prostate cancer J Urol 183 2010 1779 1785
17. A. Adamy, D.S. Yee, and K. Matsushita et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477 482
18. M. Bul, X. Zhu, and R. Valdagni et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597 603
19. R.C. van den Bergh, S. Roemeling, and M.J. Roobol et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1 8
20. M.S. Soloway, C.T. Soloway, A. Eldefrawy, K. Acosta, B. Kava, and M. Manoharan Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 2010 831 835
21. N. van As, A.R. Norman, and K. Thomas et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 54 2008 1297 1305
22. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/ 08%20Prostate%20Cancer-LR%20March%2013th%202012.pdf. Updated 2012.
23. National Comprehensive Cancer Network clinical practice guidelines in oncology. Prostate cancer, v.1.2013. NCCN Web site. http://www.nccn.org/ professionals/physician-gls/pdf/prostate.pdf.
24. National Institute for Health and Clinical Excellence clinical guideline 58. Prostate cancer: diagnosis and treatment. Updated 2008. NICE Web site. http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline.pdf.
25. G. Draisma, R. Postma, F. Schröder, T. van der Kwast, and H. de Koning Gleason score, age and screening: modeling dedifferentiation in prostate cancer Int J Cancer 119 2006 2366 2371
26. M.A. Dall'Era, B.R. Konety, and J.E. Cowan et al. Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664 2670
27. V. Fradet, J. Kurhanewicz, and J. Cowan et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging Radiology 256 2010 176 183
28. A.V. Taira, G.S. Merrick, and R.W. Galbreath et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting Prostate Cancer Prostatic Dis 13 2010 71 77
29. A. Finelli, G. Trottier, and N. Lawrentschuk et al. Impact of 5-alpha-reductase inhibitors on men followed by active surveillance for prostate cancer Eur Urol 59 2011 509 514